Search
for
Sort by
Research 31–60 of 121
- WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
- Efficacy and Safety of Thermobalancing Therapy in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia was Confirmed by Clinical Trial
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Five-alpha-reductase Inhibitors for prostate cancer prevention.
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
- Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials
- Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
- Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
- Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
- 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?
- Total prostate volume as risk factor for semen pathologies in ageing male
- Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
- UP-02.011 Biofeedback Treatment for Dysfunctional Voiding Diagnosed in Adulthood
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
- The Experience of SARS-CoV-2 in Patients with Benign Prostatic Hyperplasia: Is There Any Correlation between Them?
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
- 1408 INDUCTION OF SECRETED WNT FACTOR WISP1/CCN4 BY HUMAN PROSTATE STROMAL CELLS BY MICROENVIORNMENTAL HYPOXIA
- 1407 ANDROGENETIC ALOPECIA, PROSTATE VOLUME AND URINARY SYMPTOMS. IS THERE A RELATIONSHIP? A CASE-CONTROL STUDY
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
- Discontinuation of Alpha-Blockade after Initial Treatment with Finasteride and Doxazosin for Bladder Outlet Obstruction
- The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
- Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study
- 1748 IS ANDROGENETIC ALOPECIA ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA? ANALYSIS OF 907 PATIENTS
- What do we know about phytotherapy of benign prostatic hyperplasia?
- 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review